Deeptak Verma
Merck & Co.
36 Papers
78 Citations
Deeptak Verma is an academic researcher from Merck & Co.. The author has contributed to research in topics: Chemistry & Biology. The author has an hindex of 11, co-authored 30 publications. Previous affiliations of Deeptak Verma include University of North Carolina at Chapel Hill & Dartmouth College.
Chat about Author
Papers
Design of an in vitro biocatalytic cascade for the manufacture of islatravir
Mark A. Huffman,Anna Fryszkowska,Oscar Alvizo,Margie Borra-Garske,Kevin R. Campos,Canada Keith A,Paul N. Devine,Da Duan,Jacob Forstater,Shane T. Grosser,Holst M. Halsey,Gregory Hughes,Junyong Jo,Leo A. Joyce,Joshua N. Kolev,Jack Liang,Kevin M. Maloney,Benjamin F. Mann,Nicholas M. Marshall,Mark McLaughlin,Jeffrey C. Moore,Grant S. Murphy,Christopher C. Nawrat,Jovana Nazor,Scott J. Novick,Niki R. Patel,Agustina Rodriguez-Granillo,Sandra A. Robaire,Edward C. Sherer,Matthew D. Truppo,Aaron M. Whittaker,Deeptak Verma,Li Xiao,Yingju Xu,Hao Yang +34 more
TL;DR: An in vitro biocatalytic cascade synthesis of the investigational HIV treatment islatravir is reported, requiring fewer than half the number of steps of the previously reported routes.
492
Engineered ribosyl-1-kinase enables concise synthesis of molnupiravir, an antiviral for covid-19
John A. McIntosh,Tamas Benkovics,Steven M. Silverman,Mark A. Huffman,Jongrock Kong,Peter E. Maligres,Tetsuji Itoh,Hao Yang,Deeptak Verma,Weilan Pan,Hsing-I Ho,Jonathan Vroom,Anders M. Knight,Jessica A. Hurtak,Artis Klapars,Anna Fryszkowska,William J. Morris,Neil A. Strotman,Grant S. Murphy,Kevin M. Maloney,Patrick S. Fier +20 more
TL;DR: In this paper, a short and sustainable synthesis of molnupiravir (MK-4482) from simple raw materials that would minimize the time needed to manufacture and supply moln upiravirus was proposed, enabled by the invention of a novel biocatalytic cascade featuring an engineered ribosyl-1kinase and uridine phosphorylase.
138
A kinase-cGAS cascade to synthesize a therapeutic STING activator
John A. McIntosh,Zhijian Liu,Brian M. Andresen,Nastaran Salehi Marzijarani,Jeffrey S. Moore,Nicholas M. Marshall,Margie Borra-Garske,Jennifer V. Obligacion,Patrick S. Fier,Feng Peng,Jacob Forstater,Matthew S. Winston,Chihui An,Wonsuk Chang,Jongwon Lim,Mark A. Huffman,Steven P. Miller,Fuh-Rong Tsay,Michael D. Altman,Charles A. Lesburg,Dietrich Steinhuebel,B. Wesley Trotter,Jared N. Cumming,Alan B. Northrup,Xiaodong Bu,Benjamin F. Mann,Mirlinda Biba,Kaori Hiraga,Grant S. Murphy,Joshua N. Kolev,Amanda M. Makarewicz,Weilan Pan,Iman Farasat,Rachel S Bade,Kevin Stone,Da Duan,Oscar Alvizo,Donovan Adpressa,Erik D. Guetschow,Erik Hoyt,Erik L. Regalado,Steve Castro,Nelo R. Rivera,Joseph P. Smith,Fengqiang Wang,Alejandro Crespo,Deeptak Verma,Stephanus Axnanda,Zachary E.X. Dance,Paul N. Devine,David M. Tschaen,Keith Canada,Paul G. Bulger,Benjamin D. Sherry,Matthew D. Truppo,Rebecca T. Ruck,L.-C. Campeau,David Jonathan Bennett,Guy R. Humphrey,Kevin R. Campos,Matthew L. Maddess +60 more
TL;DR: The substantial capacity that currently exists to use biosynthetic approaches to discover and manufacture complex, non-natural molecules is demonstrated.
86
Changes in Lysozyme Flexibility upon Mutation Are Frequent, Large and Long-Ranged
TL;DR: Small structural perturbations introduced by single point mutations have a frequent and pronounced affect on lysozyme flexibility that can extend over long distances, and results suggest compensating mutations in HEWL reestablish desired properties.
Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity
Regina S. Salvat,Deeptak Verma,Andrew S. Parker,Jack R Kirsch,Seth A. Brooks,Chris Bailey-Kellogg,Karl E. Griswold +6 more
TL;DR: It is demonstrated that a multiobjective library-design method enables incorporation of mutations throughout the protein, modifying portions that trigger immune recognition while simultaneously preserving stability and catalytic activity, and could enable functional deimmunization of other biotherapeutic agents.
39